Latest News
HOPA and CMRignite Launch "Time to Talk Diversity in Clinical Trials" Campaign
HOPA and CMRignite have collaborated on "Time to Talk Diversity in Clinical Trials," a campaign to address the critical need for increased diversity in cancer clinical research and ensure that all patient populations are adequately represented.
Pharmacist’s Application to Practice: Axatilimab-csfr
Sydney Hunt, PharmD, PGY-1 Pharmacist Resident, and Lindsay Orton, PharmD, BCOP, Stem Cell Transplant and Cellular Therapy Clinical Pharmacist, both from Vanderbilt University Medical Center, Nashville, TN, write about axatilimab-csfr (Niktimvo).
Explore more from HOPA
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously